INTERNATIONAL PATENT: VERTEX PHARMACEUTICALS INCORPORATED FILES APPLICATION FOR "COMBINATION COMPRISING EXACAFTOR/TEZACAFTOR/IVACAFTOR FOR USE IN TREATING CYSTIC FIBROSIS WHERE THE PATIENT HAS AT LEAST ONE CFTR MUTATION"

GENEVA, Jan. 7 -- VERTEX PHARMACEUTICALS INCORPORATED (50 Northern AvenueBoston, Massachusetts 02210) filed a patent application (PCT/US2025/035573) for "COMBINATION COMPRISING EXACAFTOR/TEZACAFTOR/IVACAFTOR FOR USE IN TREATING CYSTIC FIBROSIS WHERE THE PATIENT HAS AT LEAST ONE CFTR MUTATION" on Jun 27, 2025. With publication no. WO/2026/006653, the details related to the patent application was published on Jan 02, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): VAN GOOR, Fredrick (50 Northern AvenueBoston, Massachusetts 02210)

Abstract: The present disclosure relates to methods of treating...